全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2015 

携带CIP2A shRNA重组腺相关病毒载体的构建及其鉴定
Construction and appraisal of recombinant adeno-associated virus vector for expressing shRNA targeting CIP2A mRNA

DOI: 10.7652/jdyxb201506006

Keywords: CIP2A,RNA干扰,重组腺相关病毒,短发卡RNA
cancerous inhibitor of PP2A (CIP2A)
,RNA interference,recombinant adeno-associated virus (rAAV),short hairpin RNA (shRNA)

Full-Text   Cite this paper   Add to My Lib

Abstract:

摘要:目的 构建携带CIP2A shRNA重组腺相关病毒载体,制备靶向性沉默CIP2A表达的高浓度重组腺相关病毒。方法 设计合成CIP2A shRNA,退火形成双链与pDC316-EGFP-U6质粒BamHⅠ和HindⅢ双酶切产物相连接构建形成质粒pDC316-EGFP-CIP2A shRNA,以鉴定正确的pDC316-EGFP-CIP2A shRNA克隆为模板PCR扩增EGFP-CIP2A shRNA片段,EcoRⅠ和SalⅠ双酶切PCR扩增产物及pSNAV2.0质粒后进行连接形成重组质粒pSNAV2.0-EGFP-CIP2A shRNA,建立载体细胞株BHK/CIP2A-shRNA,采用AAV MaxTM包装系统大规模制备rAAV2-EGFP-CIP2A shRNA并对其纯化及滴度测定。将rAAV2-EGFP-CIP2A shRNA感染肝癌细胞HepG2,利用空载病毒载体rAAV2-EGFP作对照,采用Real-time PCR及Western blot方法检测CIP2A shRNA基因沉默效果。结果 携带编码CIP2A shRNA腺相关病毒载体质粒pSNAV2.0-EGFP-CIP2A shRNA经双酶切及测序鉴定,质粒构建正确;将重组质粒与辅助病毒HSV1-rc/ΔUL2共转染包装细胞BHK-21,成功制备重组腺相关病毒rAAV2-CIP2A shRNA,经测定纯化所得rAVV2病毒滴度为0.25×1012v.g./mL。筛选MOI值为1×105感染肝癌细胞HepG2,CIP2A mRNA及蛋白表达水平分别于感染后24h和48h与对照细胞相比出现明显下降。结论 成功制备高滴度携带CIP2A shRNA重组腺相关病毒载体rAAV2-CIP2A shRNA。
ABSTRACT: Objective To construct the recombinant adeno-associated virus vector carrying cancerous inhibitor of PP2A (CIP2A) short hairpin RNA (shRNA) for preparation of high-titer viruses. Methods The small hairpin RNA of CIP2A (CIP2A shRNA) was designed, synthesized and cloned into pDC316-EGFP-U6 plasmid which was double digested by BamHⅠ and HindⅢ. The resultant plasmid pDC316-EGFP-shRNA was confirmed and served as template to appraise primers. EGFP-CIP2A shRNA sequence was amplified by PCR, double digested with EcoRⅠ and SalⅠ and ligated to pSNAV2.0 plasmid digested with the same enzyme pair. pSNAV2.0-EGFP-CIP2A shRNA plasmid DNA was prepared, purified, identified and transfected into BHK-21 cells. BHK-21 cells expressing CIP2A shRNA (BHK-21/CIP2A-shRNA) were obtained and subsequently infected with VGTC’s proprietary AAV packaging system to package the rAAV2-CIP2A shRNA. After purification, the functional and infectious virus was obtained and the titer of virus was detected. Real-time PCR and Western blot methods were used to detect the expression of CIP2A after infection with HepG2 cells, and the empty viral vector rAAV2-EGFP was used as control. Results A recombinant adeno-associated virus-2 vector carrying CIP2A shRNA was constructed successfully. The presence of the target sequence in the vector was confirmed by double enzyme digestion and sequencing. By transfecting the pSNAV2.0-EGFP-CIP2A shRNA plasmid into BHK-21 cells, BHK-21/CIP2A shRNA cells were infected with helper virus HSV1-rc/ΔUL2 to package the rAAV2-CIP2A shRNA to obtain a functional and infectious virus. The titer of the recombinant virus was 0.25×1012 v.g./mL. The expression of CIP2A mRNA and protein was decreased significantly after infection for 24h and 48h as compared with that of the controls by screening value of 1×105 MOI effected HepG2

References

[1]  KHANNA A, PIMANDA JE, WESTERMARCK J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target[J]. Cancer Res, 2013, 73(22):6548-6553.
[2]  杨雪,宋涛,杨威,等. CIP2A在肝癌组织中的表达及其临床意义[J]. 西安交通大学学报:医学版, 2011, 32(4):477-480.
[3]  DE P, CARLSON J, LEYLAND-JONES B, et al. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands[J]. Oncotarget, 2014, 5(13):4581-4602.
[4]  CHEN KF, LIU CY, LIN YC, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells[J]. Oncogene, 2010, 29(47):6257-6266.
[5]  KIM NY, BAEK JY, CHOI HS, et al. Short-hairpin RNA-mediated gene expression interference in Trichoplusia ni cells[J]. J Microbiol Biotechnol, 2012, 22(2):190-198.
[6]  DISMUKE DJ, TENENBAUM L, SAMULSKI RJ. Biosafety of recombinant adeno-associated virus vectors[J]. Curr Gene Ther, 2013, 13(6):434-452.
[7]  KHANNA A, BOCKELMAN C, HEMMES A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer[J]. J Natl Cancer Inst, 2009, 101(11):793-805.
[8]  JUNTTILA MR, PUUSTINEN P, NIEMELA M, et al. CIP2A inhibits PP2A in human malignancies[J]. Cell, 2007, 130(1):51-62.
[9]  钱安平,辛彦,肖玉平. CIP2A与肿瘤关系的研究进展[J]. 世界华人消化杂志, 2009, 17(26):2700-2704.
[10]  TAKIZAWA T, GEMMA A, UI-TEI K, et al. Basic and clinical studies on functional RNA molecules for advanced medical technologies[J]. J Nippon Med Sch, 2010, 77(2):71-79.
[11]  李金峰,彭书??. 小干扰RNA的设计方法及研究进展[J]. 吉林大学学报:医学版, 2012, 38(1):167-170.
[12]  HATTORI Y. Development of non-viral vector for cancer gene therapy[J]. Yakugaku Zasshi, 2010, 130(7):917-923.
[13]  AUMAN JT. Gene therapy: Have the risks associated with viral vectors been solved?[J]. Curr Opin Mol Ther, 2010, 12(6):637-638.
[14]  DISMUKE DJ, TENENBAUM L, SAMULSKI RJ. Biosafety of recombinant adeno-associated virus vectors[J]. Curr Gene Ther, 2013, 13(6):434-452.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133